Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study
ABSTRACT Main Problem The efficacy and safety of platinum‐based chemotherapy with programmed death‐1 (PD‐1) blockade after chemoradiotherapy (CRT) for the treatment of limited disease (LD) small cell lung cancer (SCLC) is unknown. This study aimed to assess the effectiveness and tolerability of plat...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.70118 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849432312607932416 |
|---|---|
| author | Ayako Shiono Hisao Imai Kyoichi Kaira Takanori Abe Yuki Sato Ken Yamamoto Hiroki Watanabe Yuko Tsuchiya‐Kawano Akihiro Tamiya Takashi Osaki Noriko Yanagitani Shigeru Tanzawa Toshiyuki Sumi Kohei Yoshimine Yohei Matsui Satoshi Endo Kazuhiko Shibata Shinnosuke Takemoto Yosuke Miura Yoshiaki Nagai Junichi Nakagawa Takeshi Tsuda Hiroshi Kagamu |
| author_facet | Ayako Shiono Hisao Imai Kyoichi Kaira Takanori Abe Yuki Sato Ken Yamamoto Hiroki Watanabe Yuko Tsuchiya‐Kawano Akihiro Tamiya Takashi Osaki Noriko Yanagitani Shigeru Tanzawa Toshiyuki Sumi Kohei Yoshimine Yohei Matsui Satoshi Endo Kazuhiko Shibata Shinnosuke Takemoto Yosuke Miura Yoshiaki Nagai Junichi Nakagawa Takeshi Tsuda Hiroshi Kagamu |
| author_sort | Ayako Shiono |
| collection | DOAJ |
| description | ABSTRACT Main Problem The efficacy and safety of platinum‐based chemotherapy with programmed death‐1 (PD‐1) blockade after chemoradiotherapy (CRT) for the treatment of limited disease (LD) small cell lung cancer (SCLC) is unknown. This study aimed to assess the effectiveness and tolerability of platinum‐based chemotherapy with PD‐1 blockade in patients with recurrent LD‐SCLC after CRT. Methods This retrospective study analyzed 66 patients who experienced recurrence after CRT for LD‐SCLC and received platinum‐based chemotherapy with PD‐1 blockade therapy between August 2019 and September 2020 at 19 Japanese institutions. Clinical efficacy was assessed according to response rate, survival, and toxicity. Results The overall response rate was 53.0% (95% confidence interval [CI], 48.9–65.0), and the disease control rate was 78.7% (95% CI, 68.9–88.5). The median progression‐free survival and overall survival periods were 5.9 (95% CI, 4.7–7.3) months and 24.9 (95% CI, 16.8–28.1) months, respectively. The frequencies of grade ≥ 3 hematological adverse events were as follows: leukopenia, 47.0%; neutropenia, 65.2%; and febrile neutropenia, 8.3%. There was no treatment‐related death. Conclusions Chemoimmunotherapy is a feasible and effective treatment for recurrent disease after CRT in patients with LD‐SCLC, providing a new potential option for the pharmacological management of these patients. |
| format | Article |
| id | doaj-art-cbf19b6b4e024aeabe885883a90f00df |
| institution | Kabale University |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-cbf19b6b4e024aeabe885883a90f00df2025-08-20T03:27:23ZengWileyThoracic Cancer1759-77061759-77142025-07-011613n/an/a10.1111/1759-7714.70118Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective StudyAyako Shiono0Hisao Imai1Kyoichi Kaira2Takanori Abe3Yuki Sato4Ken Yamamoto5Hiroki Watanabe6Yuko Tsuchiya‐Kawano7Akihiro Tamiya8Takashi Osaki9Noriko Yanagitani10Shigeru Tanzawa11Toshiyuki Sumi12Kohei Yoshimine13Yohei Matsui14Satoshi Endo15Kazuhiko Shibata16Shinnosuke Takemoto17Yosuke Miura18Yoshiaki Nagai19Junichi Nakagawa20Takeshi Tsuda21Hiroshi Kagamu22Department of Respiratory Medicine Saitama Medical University International Medical Center Hidaka Saitama JapanDepartment of Respiratory Medicine Saitama Medical University International Medical Center Hidaka Saitama JapanDepartment of Respiratory Medicine Saitama Medical University International Medical Center Hidaka Saitama JapanDepartment of Radiation Oncology Saitama Medical University International Medical Center Hidaka Saitama JapanDepartment of Respiratory Medicine Kobe City Medical Center General Hospital Kobe Hyogo JapanDivision of Thoracic Oncology Kobe Minimally Invasive Cancer Center Kobe Hyogo JapanDepartment of Internal Medicine Niigata Cancer Center Hospital Niigata Niigata JapanDepartment of Respiratory Medicine Kitakyushu Municipal Medical Center Kitakyushu Fukuoka JapanDepartment of Internal Medicine NHO Kinki‐Chuo Chest Medical Center Sakai Osaka JapanDepartment of Respiratory Medicine NHO Shibukawa Medical Center Shibukawa Gunma JapanDepartment of Thoracic Medical Oncology The Cancer Institute Hospital of Japanese Foundation for Cancer Research Koto‐ku Tokyo JapanDivision of Medical Oncology, Department of Internal Medicine Teikyo University School of Medicine Itabashi‐ku Tokyo JapanDepartment of Pulmonary Medicine Hakodate Goryoukaku Hospital Hakodate Hokkaido JapanDepartment of Respiratory Medicine Iizuka Hospital Iizuka Fukuoka JapanDepartment of Pulmonary Medicine Kyoto Prefectural University of Medicine Kyoto Kyoto JapanDivision of Respiratory Medicine Gunma Prefectural Cancer Center Ota Gunma JapanDivision of Medical Oncology, Department of Medicine Kouseiren Takaoka Hospital Takaoka Toyama JapanDepartment of Respiratory Medicine Nagasaki University Graduate School of Biomedical Sciences Nagasaki Nagasaki JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Jichi Medical University, Saitama Medical Center Saitama Saitama JapanDepartment of Respiratory Medicine NHO Takasaki General Medical Center Takasaki Gunma JapanDivision of Respiratory Medicine Toyama Prefectural Central Hospital Toyama Toyama JapanDepartment of Respiratory Medicine Saitama Medical University International Medical Center Hidaka Saitama JapanABSTRACT Main Problem The efficacy and safety of platinum‐based chemotherapy with programmed death‐1 (PD‐1) blockade after chemoradiotherapy (CRT) for the treatment of limited disease (LD) small cell lung cancer (SCLC) is unknown. This study aimed to assess the effectiveness and tolerability of platinum‐based chemotherapy with PD‐1 blockade in patients with recurrent LD‐SCLC after CRT. Methods This retrospective study analyzed 66 patients who experienced recurrence after CRT for LD‐SCLC and received platinum‐based chemotherapy with PD‐1 blockade therapy between August 2019 and September 2020 at 19 Japanese institutions. Clinical efficacy was assessed according to response rate, survival, and toxicity. Results The overall response rate was 53.0% (95% confidence interval [CI], 48.9–65.0), and the disease control rate was 78.7% (95% CI, 68.9–88.5). The median progression‐free survival and overall survival periods were 5.9 (95% CI, 4.7–7.3) months and 24.9 (95% CI, 16.8–28.1) months, respectively. The frequencies of grade ≥ 3 hematological adverse events were as follows: leukopenia, 47.0%; neutropenia, 65.2%; and febrile neutropenia, 8.3%. There was no treatment‐related death. Conclusions Chemoimmunotherapy is a feasible and effective treatment for recurrent disease after CRT in patients with LD‐SCLC, providing a new potential option for the pharmacological management of these patients.https://doi.org/10.1111/1759-7714.70118chemoradiotherapylimited disease small cell lung cancerPD‐1 blockaderecurrenceretrospective |
| spellingShingle | Ayako Shiono Hisao Imai Kyoichi Kaira Takanori Abe Yuki Sato Ken Yamamoto Hiroki Watanabe Yuko Tsuchiya‐Kawano Akihiro Tamiya Takashi Osaki Noriko Yanagitani Shigeru Tanzawa Toshiyuki Sumi Kohei Yoshimine Yohei Matsui Satoshi Endo Kazuhiko Shibata Shinnosuke Takemoto Yosuke Miura Yoshiaki Nagai Junichi Nakagawa Takeshi Tsuda Hiroshi Kagamu Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study Thoracic Cancer chemoradiotherapy limited disease small cell lung cancer PD‐1 blockade recurrence retrospective |
| title | Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study |
| title_full | Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study |
| title_fullStr | Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study |
| title_full_unstemmed | Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study |
| title_short | Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study |
| title_sort | significance of platinum based chemotherapy with programmed death 1 blockade in limited disease small cell lung cancer a retrospective study |
| topic | chemoradiotherapy limited disease small cell lung cancer PD‐1 blockade recurrence retrospective |
| url | https://doi.org/10.1111/1759-7714.70118 |
| work_keys_str_mv | AT ayakoshiono significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT hisaoimai significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT kyoichikaira significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT takanoriabe significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT yukisato significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT kenyamamoto significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT hirokiwatanabe significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT yukotsuchiyakawano significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT akihirotamiya significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT takashiosaki significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT norikoyanagitani significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT shigerutanzawa significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT toshiyukisumi significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT koheiyoshimine significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT yoheimatsui significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT satoshiendo significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT kazuhikoshibata significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT shinnosuketakemoto significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT yosukemiura significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT yoshiakinagai significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT junichinakagawa significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT takeshitsuda significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy AT hiroshikagamu significanceofplatinumbasedchemotherapywithprogrammeddeath1blockadeinlimiteddiseasesmallcelllungcanceraretrospectivestudy |